FDA approves Shire's Vyvanse for binge-eating disorder

By Toni Clarke WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Friday approved Shire Plc's stimulant Vyvanse to treat binge-eating disorder, the first product to be approved for the condition. Vyvanse, which is currently approved to treat attention deficit hyperactivity disorder, generated sales of more than $1 billion in the first nine months of last year. Dr. Flemming Ornskov, the company's chief executive officer, said in an interview that Shire's goal is to generate overall sales of $10 billion by 2020. Of that, he expects $200 million to $300 million to come from Vyvanse for binge-eating.



via Health News Headlines - Yahoo News http://ift.tt/1tGLCi7